Literature DB >> 20443090

Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo.

Yue Huang1, Xiao-Mei Chen, Bing-Xiang Zhao, Xi-Yu Ke, Bo-Jun Zhao, Xin Zhao, Ying Wang, Xuan Zhang, Qiang Zhang.   

Abstract

The purpose of this present study was to evaluate the antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX). The SSL-PTX was prepared by the thin-film method. The release of paclitaxel from SSL-PTX was analyzed using a dialysis method. The effect of SSL-PTX on endothelial cell proliferation and migration was investigated in vitro. The antitumor and antiangiogenic activity of SSL-PTX was evaluated in MDA-MB-231 tumor xenograft growth in BALB/c nude mice. The release of paclitaxel from SSL-PTX was 22% within 24 h. Our in vitro results indicated that SSL-PTX could effectively inhibit the endothelial cell proliferation and migration at a concentration-dependent manner. We also observed that metronomic SSL-PTX induced marked tumor growth inhibition in MDA-MB-231 xenograft model via the antiangiogenic mechanism, unlike that in paclitaxel injection (Taxol) formulated in Cremophor EL (CrEL). Overall, our results suggested that metronomic chemotherapy with low-dose, CrEL-free SSL-PTX should be feasible and effective.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20443090      PMCID: PMC2902309          DOI: 10.1208/s12249-010-9430-z

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  39 in total

1.  Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2).

Authors:  A W Ashton; R Yokota; G John; S Zhao; S O Suadicani; D C Spray; J A Ware
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

Review 2.  The anti-angiogenic basis of metronomic chemotherapy.

Authors:  Robert S Kerbel; Barton A Kamen
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

3.  Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy.

Authors:  Marcus Schmitt-Sody; Sebastian Strieth; Senat Krasnici; Birgitta Sauer; Brita Schulze; Michael Teifel; Uwe Michaelis; Kurt Naujoks; Marc Dellian
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

4.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Authors:  T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

5.  Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model.

Authors:  Rainer Kunstfeld; Georg Wickenhauser; Uwe Michaelis; Michael Teifel; Wolfgang Umek; Kurt Naujoks; Klaus Wolff; Peter Petzelbauer
Journal:  J Invest Dermatol       Date:  2003-03       Impact factor: 8.551

Review 6.  The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer.

Authors:  Yago Nieto
Journal:  Haematologica       Date:  2003-02       Impact factor: 9.941

7.  Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer.

Authors:  Christian Bode; Lutz Trojan; Christel Weiss; Bettina Kraenzlin; Uwe Michaelis; Michael Teifel; Peter Alken; Maurice Stephan Michel
Journal:  Oncol Rep       Date:  2009-08       Impact factor: 3.906

8.  Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature.

Authors:  Sebastian Strieth; Martin E Eichhorn; Birgitta Sauer; Brita Schulze; Michael Teifel; Uwe Michaelis; Marc Dellian
Journal:  Int J Cancer       Date:  2004-05-20       Impact factor: 7.396

9.  Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.

Authors:  Sylvia S W Ng; William D Figg; Alex Sparreboom
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

Review 10.  Antivascular and antitumor activities of liposome-associated drugs.

Authors:  Robert M Straubinger; Robert D Arnold; Rong Zhou; Richard Mazurchuk; Jeanine E Slack
Journal:  Anticancer Res       Date:  2004 Mar-Apr       Impact factor: 2.480

View more
  8 in total

Review 1.  Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.

Authors:  Guido Bocci; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

2.  Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma: in vivo murine model.

Authors:  Juan Riestra-Ayora; Carolina Sánchez-Rodríguez; Raquel Palao-Suay; Joaquín Yanes-Díaz; Ana Martín-Hita; María Rosa Aguilar; Ricardo Sanz-Fernández
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

3.  Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.

Authors:  Lulu Cai; Xianhuo Wang; Wenwen Wang; Neng Qiu; Jiaolin Wen; Xingmei Duan; Xia Li; Xiang Chen; Li Yang; Zhiyong Qian; Yuquan Wei; Lijuan Chen
Journal:  Int J Nanomedicine       Date:  2012-08-14

Review 4.  The pharmacological bases of the antiangiogenic activity of paclitaxel.

Authors:  Guido Bocci; Antonello Di Paolo; Romano Danesi
Journal:  Angiogenesis       Date:  2013-02-07       Impact factor: 9.596

5.  Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation.

Authors:  Yu Duan; Xin Zhao; Wei Ren; Xin Wang; Ke-Fu Yu; Dan Li; Xuan Zhang; Qiang Zhang
Journal:  Onco Targets Ther       Date:  2013-03-14       Impact factor: 4.147

6.  Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model.

Authors:  Jia Lin; Sarah Shigdar; Ding Zhi Fang; Dognxi Xiang; Ming Q Wei; Andrew Danks; Lingxue Kong; Lianghong Li; Liang Qiao; Wei Duan
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

7.  Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy.

Authors:  Dan Huang; Shuang Zhang; Ting Zhong; Wei Ren; Xin Yao; Yang Guo; Xiao-Chuan Duan; Yi-Fan Yin; Shu-Shi Zhang; Xuan Zhang
Journal:  Oncotarget       Date:  2016-07-12

8.  Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid.

Authors:  Zhuo-Yue Li; Yi-Fan Yin; Yang Guo; Hui Li; Mei-Qi Xu; Man Liu; Jing-Ru Wang; Zhen-Han Feng; Xiao-Chuan Duan; Shuang Zhang; Shuai-Qiang Zhang; Guang-Xue Wang; Ai Liao; Shu-Min Wang; Xuan Zhang
Journal:  Int J Nanomedicine       Date:  2020-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.